10-Q: Shuttle Pharmaceuticals Reports Q2 2024 Results, Faces Going Concern Challenges

Shuttle Pharmaceuticals reported a net loss of $3.8 million for the first half of 2024 and faces substantial doubt about its ability to continue as a going concern.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. reported a net loss of approximately $3.8 million for the six months ended June 30, 2024, with no revenue.
• The company's working capital was approximately $1.1 million as of June 30, 2024.
• The company has incurred losses since its inception.
• A convertible note payable includes covenants and certain cash payment requirements.
• The company informed the investor of its convertible note that the expected restatement of its financial statements for the years ended December 31, 2022 and 2023 constituted an event of default.
• The company paid $0.6 million to the investor of the convertible note and received a waiver related to the default, with the funds being held as collateral.
• These conditions raise substantial doubt about the company's ability to continue as a going concern within one year.
• The company's existing cash resources, marketable securities, and cash from equity offerings and convertible notes are not expected to be sufficient to fund operations and clinical trials for the next twelve months.
• The company is pursuing additional financing, including a SBIR grant and other options.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.

Sentiment

Score: 2

Explanation: The document indicates significant financial challenges, including a going concern warning, substantial losses, ineffective controls, and a need for significant capital raising. The sentiment is negative due to the high level of risk and uncertainty surrounding the company's future.

Positives

• The company has completed the manufacturing of the active pharmaceutical ingredient for Ropidoxuridine.
• The company has received FDA approval to begin the clinical trial for Ropidoxuridine.
• The Institutional Review Board (IRB) has approved the Phase II clinical trial.
• The company is actively pursuing additional financing options, including a SBIR grant and a $10 million capital raise.
• The company has engaged a CRO to oversee the Phase II clinical trial.

Negatives

• The company has incurred significant losses since inception.
• The company has a net loss of $3.8 million for the first half of 2024.
• The company's working capital is low at $1.1 million.
• The company's existing cash resources are not expected to be sufficient to fund operations and clinical trials for the next twelve months.
• The company defaulted on its convertible note, requiring a payment of $0.6 million for a waiver.
• The company's disclosure controls and procedures were deemed ineffective as of June 30, 2024.
• The company has identified material weaknesses in its internal controls over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company may not be able to successfully raise additional equity or debt financing.
• The company's clinical trials may encounter problems that cause delays or suspensions.
• The company's patents may be challenged, invalidated, or circumvented.
• The company's internal controls over financial reporting have material weaknesses.
• The company's disclosure controls and procedures are ineffective.
• The company's financial statements for 2022 and 2023 required restatement.

Future Outlook

The company's ability to continue as a going concern is dependent on its ability to raise additional capital to fund ongoing operations, conduct clinical trials, and bring a drug candidate to commercialization. The company is pursuing a $10 million capital raise and a SBIR grant.

Management Comments

• Management has initiated a $4.5 million rights offering and submitted an application for a SBIR grant for non-dilutive funding.
• Management is committed to maintaining a strong internal control environment.
• Management will continue to monitor and evaluate the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and is committed to taking further action and implementing additional improvements as necessary.

Industry Context

The company is operating in the competitive pharmaceutical industry, focusing on cancer therapies. The company's approach of using radiation sensitization and HDAC inhibitors is aligned with current trends in cancer treatment. The company's reliance on external funding and the need for regulatory approvals are typical challenges in this industry.

Comparison to Industry Standards

• Shuttle Pharmaceuticals is a development-stage company, and its financial results are not directly comparable to established pharmaceutical companies with commercial products.
• The company's reliance on convertible debt financing is common among early-stage biotech companies, but the high interest rate of 218% on the Alto Convertible Note is significantly higher than typical debt financing.
• The company's research and development expenses are typical for a company in its stage of development, but the lack of revenue and the need for additional capital raise concerns about its long-term viability.
• The company's internal control weaknesses are a significant concern and are not typical for a publicly traded company, especially one that has been listed for a number of years.
• The company's need to restate its financial statements for 2022 and 2023 is a serious issue and is not typical for a company that has been listed for a number of years.

Management Changes

Related Party Transactions

• The company had a manufacturing agreement with TCG GreenChem, Inc., where one of the company's independent directors is CEO and CSO.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern warning.
• Employees may be impacted by potential cost-cutting measures or the company's inability to continue operations.
• Customers may be impacted by delays or cancellations of clinical trials and product development.
• Suppliers and creditors face increased risk of non-payment due to the company's financial challenges.

Next Steps

• The company will continue to pursue additional financing options.
• The company will continue to work on the Phase II clinical trial for Ropidoxuridine.
• The company will continue to implement measures to remediate material weaknesses in internal controls.
• The company will continue to monitor and evaluate the effectiveness of its internal controls and procedures over financial reporting.

Key Dates

Keywords

Ropidoxuridine, clinical trial, cancer therapy, HDAC inhibitors, convertible note, going concern, financial results, capital raise, SBIR grant, internal controls